fda regulations semaglutide Do GLP-1 Patches Really Work? Evidence and FDA-Approved Alternatives FDA ends semaglutide shortage, closing

The unanswered questions are just as important: long-term risk, final labeling, real-world tolerability, and appropriate access

Hompesch, M

The GIP component adds: Enhanced Insulin Response: Even stronger blood sugar control than GLP-1 alone Better insulin secretion timing Improved insulin sensitivity in tissues Fat Metabolism Effects: GIP receptors exist in fat tissue May influence how body stores and uses fat Potentially increases fat burning Synergistic Appetite Suppression: GIP and GLP-1 together produce greater appetite reduction More potent satiety signals Stronger overall effect This explains why tirzepatide produces 5-7% more weight loss than semaglutidethe dual action is more powerful than GLP-1 alone

For semaglutide, the maintenance dose for weight management is 2.4 mg weekly, significantly higher than the 0.5-1.0 mg doses used for diabetes management